Lymphomas & Lymphoid Neoplasia

Lymphomas & Lymphoid Neoplasia

A collection of features and news articles published in ASH Clinical News related to lymphomas and lymphoid neoplasia.

Are Survivors of Childhood Lymphomas At Increased Risk of Cognitive Impairment?

Researchers from the Yale Cancer Center report that the systemic therapies received by survivors of childhood cancers may impact their long-term cognitive outcomes, with...

R2CHOP Benefits Patients With Untreated Diffuse Large B-Cell Lymphoma, Regardless of Subtype

For patients with previously untreated diffuse large B-cell lymphoma (DLBCL), adding lenalidomide to the combination of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)...
On location

Evaluating a New Bispecific CAR T-Cell Therapy for B-Cell Lymphomas

In a first-in-human phase I clinical trial of a bispecific anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy, four of five treated patients with lymphoma...
On location

Copanlisib Plus Rituximab Improves Progression-Free Survival in Indolent Non-Hodgkin Lymphoma

Combining copanlisib with rituximab reduced the risk of progression or death by 48%, compared with placebo plus rituximab, in patients with relapsed advanced indolent...
WIB_icon

Adding Brentuximab Vedotin to Chemotherapy Improves Outcomes in Pediatric ALK-Positive ALCL

The addition of brentuximab vedotin to chemotherapy led to favorable overall survival (OS) and event-free survival (EFS) in children with ALK-positive anaplastic large cell...

Examining the Blood-Brain Barrier

The prognosis for patients with non-Hodgkin lymphoma (NHL) who develop central nervous system (CNS) relapse is dismal, and there are few clear answers about...

Axicabtagene Ciloleucel Approved for Relapsed/Refractory Follicular Lymphoma

The FDA has approved axicabtagene ciloleucel for the treatment of adult patients with relapsed or refractory indolent follicular lymphoma (FL) who have received two...

FDA Accepts sNDA for Zanubrutinib in Waldenström Macroglobulinemia

The FDA has accepted a supplemental new drug application (sNDA) for zanubrutinib for the treatment of adults with Waldenström macroglobulinemia (WM). The sNDA, submitted by...

Crizotinib Approved for Relapsed/Refractory Systemic ALCL

Crizotinib has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of children older than one year and young adults...
On location

No Difference in CNS Relapse Rate According to Prophylaxis Route

According to results from a retrospective analysis of central nervous system (CNS) prophylaxis in patients with aggressive non-Hodgkin lymphomas (NHLs), rates of CNS relapse...
Advertisement

Current Issue

May 2021 Volume 7 Issue 6

This issue provides an update on gene therapies in hematology, demystifies RNA sequencing, and more.

Block title